69. CSO of Immuno-oncology at Moderna, Tatiana Novobrantseva, on the cross-disciplinary nature of developing medicines

Episode 69. Tatiana Novobrantseva is the Chief Scientific Officer of Immuno-Oncology Research at Moderna Therapeutics. She has worked at multiple biotech companies including Verseau Therapeutics (co-founder), Third Rock Ventures/Jounce, Alnylam, Biogen, and others. Tatiana completed a PhD in Genetics at the University of Cologne and a postdoc at Harvard Medical School before jumping into the world of biotech.